[{"from": "human", "value": "Please give me some details about this molecule. [C][C][=C][C][=Branch2][Ring1][Ring2][=C][Branch1][S][C][=Branch1][N][=C][Ring1][=Branch1][C][C][=N][C][C][N][Ring1][Branch1][C][O][C][Branch1][C][C][Branch1][C][C][C]"}, {"from": "gpt", "value": "The molecule is an imidazole derivative and a potent, direct-acting alpha (\u03b1)-adrenergic agonist with affinity to both \u03b11- and \u03b12-adrenoceptors. Oxymetazoline is available in various formulations with a wide variety of clinical implications. The topical formulation of the drug is used to treat persistent facial redness in adults. As an effective decongestant, oxymetazoline is available in over-the-counter intranasal sprays used to relieve nasal and sinus congestion caused by a wide variety of conditions, such as common cold, hay fever, and upper respiratory allergies. In dentistry, oxymetazoline and tetracaine combination intranasal spray (Kovanaze) is used for regional anesthesia during dental procedures in children and adults. In July 2020, the FDA approved the use of an ophthalmic formulation of oxymetazoline (Upneeq) in adults with acquired blepharoptosis, or ptosis, making it the first FDA-approved medical treatment for this medical condition."}]